SELLAS Life Sciences Group (NASDAQ:SLS) Trading Up 8.8% – Time to Buy?

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) shares rose 8.8% during mid-day trading on Thursday . The company traded as high as $14.76 and last traded at $14.9390. Approximately 1,091,829 shares were traded during mid-day trading, a decline of 87% from the average daily volume of 8,193,203 shares. The stock had previously closed at $13.73.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Friday, July 17th. Alliance Global Partners restated a “buy” rating on shares of SELLAS Life Sciences Group in a report on Wednesday, August 12th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $10.00.

SELLAS Life Sciences Group Stock Performance

The firm’s 50 day moving average is $12.48 and its two-hundred day moving average is $8.08. The stock has a market capitalization of $2.67 billion, a PE ratio of -62.90 and a beta of 2.48.

SELLAS Life Sciences Group (NASDAQ:SLS) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01).

Institutional Investors Weigh In On SELLAS Life Sciences Group

Several large investors have recently bought and sold shares of the stock. Larson Financial Group LLC purchased a new position in shares of SELLAS Life Sciences Group in the 4th quarter valued at about $26,000. Nykredit A S acquired a new stake in shares of SELLAS Life Sciences Group during the 2nd quarter worth about $27,000. BNP Paribas Financial Markets boosted its holdings in SELLAS Life Sciences Group by 89.2% in the third quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company’s stock valued at $32,000 after purchasing an additional 9,299 shares in the last quarter. Concurrent Investment Advisors LLC purchased a new position in SELLAS Life Sciences Group in the fourth quarter valued at approximately $38,000. Finally, Beacon Pointe Advisors LLC acquired a new stake in SELLAS Life Sciences Group during the fourth quarter worth approximately $38,000. Hedge funds and other institutional investors own 17.38% of the company’s stock.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.